^
    Back
    Association details:
    Biomarker:NUP98-PRRX1 fusion
    Cancer:Acute Myelogenous Leukemia
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    idarubicin (DNA replication inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    BMC Med Genomics
    Title:

    First case report of a NUP98-PMX1 rearrangement in de novo acute myeloid leukemia and literature review

    Published date:
    05/17/2021
    Excerpt:
    A 49-year-old man diagnosed with AML...Reverse transcription-polymerase chain reaction (RT-PCR) analysis suggested the presence of the NUP98-PMX1 fusion transcript. The patient received idarubicin and cytarabine as induction chemotherapy. After 3 weeks, the BM aspirate showed complete remission...
    DOI:
    10.1186/s12920-021-00979-y